Cullinan was formed to capitalize on the latest scientific breakthroughs by advancing a dynamic portfolio of innovative, early-stage assets.

We develop both internally generated and externally sourced cancer therapeutics through a novel, cost efficient business model.

Cullinan’s goal is to leapfrog existing standards of care in cancer treatment through a unique combination of:

  • Leadership – a world-renowned scientific core team
  • Access – to breakthrough science globally
  • Business Model – reducing risk and maximizing optionality through portfolio diversification
Learn More


Cullinan is led by an accomplished team of oncology researchers, biopharma executives and experienced entrepreneurs.

Our Team
Patrick Baeuerle, Ph.D.
Patrick Baeuerle, Ph.D.Co-Founder, Chief Scientific Officer, Biologics
Owen Hughes
Owen HughesChief Executive Officer
Corinne Savill, Ph.D.
Corinne Savill, Ph.D.Chief Business Officer
Leigh Zawel, Ph.D.
Leigh Zawel, Ph.D.Chief Scientific Officer, Small Molecules


  • The Fastest Growing Therapeutic Class
  • The Largest Therapeutic Class in terms of Market Share
  • Shepherding a Period of Near Unparalleled Innovation


Access breakthrough science across a range of assets, mechanisms, and stages


Advance therapies through a cost-efficient model from preclinical to Phase 2


Create opportunities for acquisition, licensing, spin-out